Advil Allergy Sinus is a drug owned by Haleon Us Holdings Llc. It is protected by 1 US drug patent filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 28, 2027. Details of Advil Allergy Sinus's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7863287 | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines |
Feb, 2027
(2 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Advil Allergy Sinus's patents.
Latest Legal Activities on Advil Allergy Sinus's Patents
Given below is the list of recent legal activities going on the following patents of Advil Allergy Sinus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Jun, 2022 | US7863287 |
| Correspondence Address Change Critical | 05 Nov, 2019 | US7863287 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Jun, 2018 | US7863287 |
| Recordation of Patent Grant Mailed Critical | 04 Jan, 2011 | US7863287 |
| Patent Issue Date Used in PTA Calculation Critical | 04 Jan, 2011 | US7863287 |
| Email Notification Critical | 16 Dec, 2010 | US7863287 |
| Issue Notification Mailed Critical | 15 Dec, 2010 | US7863287 |
| Application Is Considered Ready for Issue Critical | 08 Dec, 2010 | US7863287 |
| Dispatch to FDC | 08 Dec, 2010 | US7863287 |
| Issue Fee Payment Received Critical | 06 Dec, 2010 | US7863287 |
Several oppositions have been filed on Advil Allergy Sinus's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Advil Allergy Sinus's generic, the next section provides detailed information on ongoing and past EP oppositions related to Advil Allergy Sinus patents.
Advil Allergy Sinus's Oppositions Filed in EPO
Advil Allergy Sinus has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 23, 2015, by Galenicum Health S.L.. This opposition was filed on patent number EP03813818A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP03813818A | Jan, 2015 | Galenicum Health S.L. | Revoked |
US patents provide insights into the exclusivity only within the United States, but Advil Allergy Sinus is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Advil Allergy Sinus's family patents as well as insights into ongoing legal events on those patents.
Advil Allergy Sinus's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Advil Allergy Sinus's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 28, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Advil Allergy Sinus Generics:
There are no approved generic versions for Advil Allergy Sinus as of now.
Alternative Brands for Advil Allergy Sinus
There are several other brand drugs using the same active ingredient (Chlorpheniramine Maleate; Ibuprofen; Pseudoephedrine Hydrochloride) as Advil Allergy Sinus. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Haleon Us Holdings |
|
About Advil Allergy Sinus
Advil Allergy Sinus is a drug owned by Haleon Us Holdings Llc. Advil Allergy Sinus uses Chlorpheniramine Maleate; Ibuprofen; Pseudoephedrine Hydrochloride as an active ingredient. Advil Allergy Sinus was launched by Haleon Us Holdings in 2002.
Approval Date:
Advil Allergy Sinus was approved by FDA for market use on 19 December, 2002.
Active Ingredient:
Advil Allergy Sinus uses Chlorpheniramine Maleate; Ibuprofen; Pseudoephedrine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Chlorpheniramine Maleate; Ibuprofen; Pseudoephedrine Hydrochloride ingredient
Dosage:
Advil Allergy Sinus is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2MG;200MG;30MG | TABLET | Over the counter | ORAL |